Enzymatica AB: Continued sales growth and breakthrough order from STADA
July 20 2017 - 1:00AM
Interim report for
Enzymatica AB (publ)
JANUARY- JUNE 2017
Continued sales growth and breakthrough order from STADA
Q2
-
Net sales reached SEK 5.9 (4.9) million.
-
Loss after tax came in at SEK -10.8 (-12.8)
million.
-
Earnings per share were SEK -0.12 (-0.20).
-
Cash and cash equivalents were SEK 18.4 (26.9)
million.
Significant events in Q2
-
Enzymatica received a record-breaking order from
the German company STADA of about SEK 12 million.
-
Enzymatica published findings of a study of
elite athletes showing that use of ColdZyme® reduced the number of
sick days by more than 50%.
H1
-
Net sales increased to SEK 15.5 (13.3)
million.
-
Loss after tax came in at SEK -22.3 (-20.9)
million.
-
Earnings per share were SEK -0.25
(-0.47).
Significant events
after Q2
Key figures |
|
|
|
|
|
(SEK million) |
Q2
2017 |
Q2
2016 |
H1
2017 |
H1
2016 |
Full year
2016 |
Net
sales |
5.9 |
4.9 |
15.5 |
13.3 |
36.5 |
Gross
margin, % |
46 |
63 |
56 |
62 |
61 |
Operating
profit/loss |
-11.8 |
-12.3 |
-23.3 |
-20.0 |
-46.2 |
Cash flow
from operating activities |
-7.4 |
-15.1 |
-16.3
|
-20.0 |
-38.4 |
Average
number of employees |
21 |
22 |
21 |
19 |
21 |
CEO statement: The STADA order confirms our
technology and increases our commercial value
The major event in the second quarter was the
ColdZyme order from the German pharmaceutical company STADA, worth
approximately SEK 12 million, for the launch in the German, Belgian
and Austrian markets. The order is the largest in Enzymatica's
history and exceeds the company's entire Q1 sales. We are now
beginning to see the results of our focus in recent years on
international distribution agreements. The order demonstrates the
commercial potential of ColdZyme and represents clear acceptance of
our technology platform.
Q2 was the 18th consecutive quarter with increased
sales compared with the same quarter of the previous year. Second
quarter sales are generally lower due to seasonal variations - yet
they increased by 21% compared with 2016. In Sweden ColdZyme sales
from pharmacies to consumers increased by more than 20% as a result
of an expanded end-customer base and a high repeat purchase rate.
For the first half of 2017 the market share in value increased to
4.6%, and sales of ColdZyme packages from Swedish pharmacies to
end-customers increased by over 20% compared with the corresponding
period in 2016. Sales from pharmacies to end-customers and from
Enzymatica to pharmacies can deviate during different periods, as a
consequence of variations in the pharmacies' inventory
build-up.
The strong sales growth in Sweden five years after
the launch demonstrates the potential for other markets where
ColdZyme will be launched through our distributors. Sales
also surged in Denmark, while we received refill orders from our
distributors in Spain and Finland during the quarter.
On 21 June we released the results of a study in
which elite athletes used ColdZyme. The study findings show that
our cold spray reduced the number of sick days, and thereby lost
practice days, by more than 50%, compared with control periods when
ColdZyme was not used. The study also showed that elite athletes
who came down with colds and used ColdZyme experienced milder cold
symptoms. The study results confirm the findings of our first
clinical study (COLDPREV I), which showed a 50%-reduction in the
number of sick days.
With the breakthrough order from STADA and the
cold season beginning after the summer we will show a strong third
quarter compared with the corresponding period in 2016.
Fredrik Lindberg, CEO
For questions about this report, please
contact:
Fredrik Lindberg, CEO, Enzymatica AB
Tel: +46 (0)708-86 53 70 | Email:
fredrik.lindberg@enzymatica.com
Bengt Jöndell, Interim CFO, Enzymatica
AB
Tel: +46 (0)703-77 71 70 | Email: bengt.jondell@enzymatica.com
Publication
This information is information that Enzymatica is obliged to make
public pursuant to the EU Market Abuse Regulation and the Swedish
Securities Markets Act (Lagen om värdepappersmarknaden). The
information was submitted for publication, through the agency of
the contact person set out above, at 08:00 CET on July 20,
2017.
Street address
Enzymatica AB (publ)
Corporate identity no.: 556719-9244
Mailing address: Ideon Science Park, 223 70 LUND
Street address: Scheelevägen 19, Ideon, Lund
Tel: +46 (0)46-286 31 00 | info@enzymatica.se |
www.enzymatica.se
Enzymatica is listed on the Nasdaq First North.
The Company is traded under the ticker symbol ENZY and ISIN code
SE0003943620.
Enzymatica's certified adviser is Erik Penser
Bankaktiebolag.
Enzymatica Q2 Eng Final
170720
This
announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Enzymatica AB via Globenewswire
ENZYMOTEC LTD. (NASDAQ:ENZY)
Historical Stock Chart
From Jun 2024 to Jul 2024
ENZYMOTEC LTD. (NASDAQ:ENZY)
Historical Stock Chart
From Jul 2023 to Jul 2024